mk2 Biotechnologies, WACKER and the Technical University of Munich (TUM) today announced their joint project targeting the development, large-scale production and purification of antimicrobial peptides (AMPs) for diverse applications.
Today, the Annual Shareholders’ Meeting approved the highest dividend in the company’s history.
Wacker Chemie AG finished Q1 2022 with new highs in sales and earnings.
As a consequence of the initial vaccine shortages in the coronavirus pandemic, the German government is securing vaccine production and supplies for the years ahead.
At today’s Capital Market Day in London, Wacker Chemie AG presents its new strategic growth targets. By 2030, the company aims to lift sales significantly while keeping profitability high.